Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SRx Health Solutions (SRXH) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for SRx Health Solutions (SRXH) over the last 16 years, with Q2 2025 value amounting to $16000.0.

  • SRx Health Solutions' Other Non Operating Income fell 8655.46% to $16000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $2.9 million, marking a year-over-year increase of 68069.71%. This contributed to the annual value of -$551000.0 for FY2022, which is 10266.15% down from last year.
  • According to the latest figures from Q2 2025, SRx Health Solutions' Other Non Operating Income is $16000.0, which was down 8655.46% from $126000.0 recorded in Q1 2025.
  • SRx Health Solutions' 5-year Other Non Operating Income high stood at $28.0 million for Q2 2021, and its period low was -$7.7 million during Q1 2021.
  • Moreover, its 5-year median value for Other Non Operating Income was -$72500.0 (2021), whereas its average is $1.4 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first crashed by 73644.25% in 2021, then soared by 80070.42% in 2023.
  • Over the past 5 years, SRx Health Solutions' Other Non Operating Income (Quarter) stood at -$69000.0 in 2021, then plummeted by 228.99% to -$227000.0 in 2022, then surged by 538.33% to $995000.0 in 2023, then surged by 166.43% to $2.7 million in 2024, then plummeted by 99.4% to $16000.0 in 2025.
  • Its last three reported values are $16000.0 in Q2 2025, $126000.0 for Q1 2025, and $2.7 million during Q3 2024.